Sign Up to like & get
recommendations!
0
Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.02.004
Abstract: Chemotherapy combining cyclophosphamide, bortezomib and dexamethasone is widely used in light-chain amyloidosis. The benefit is limited in patients with cardiac amyloidosis mainly because of adverse cardiac events. Retrospective analysis of our cohort showed that 39 patients…
read more here.
Keywords:
bortezomib dexamethasone;
cyclophosphamide bortezomib;
light;
amyloidosis ... See more keywords